EU Fast-Track Fail For Another BMS CAR-T Cell Therapy
EMA Review Of Ide-Cel Reverts To Standard Timelines; Orva-Cel Development Program Scrapped
Bristol Myers Squibb says it is common for cell and gene therapies to revert to the standard timetable as ide-cel follows liso-cel in losing its accelerated assessment status at the European Medicines Agency. Separately, the company has discontinued development of orva-cel, a CAR-T cell therapy that was earlier in the development pipeline.
